Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 2
2016 1
2017 1
2018 1
2019 3
2020 5
2021 5
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D, Schiavoni E, Turchini L, Fanali C, Alfieri N, Pizzoferrato M, Papa A, Pafundi PC, Armuzzi A, Gasbarrini A, Pugliese D, Scaldaferri F. Parisio L, et al. Among authors: pizzoferrato m. J Gastrointestin Liver Dis. 2023 Dec 22;32(4):452-459. doi: 10.15403/jgld-5084. J Gastrointestin Liver Dis. 2023. PMID: 38147610 Free article.
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study.
Graziani C, Laterza L, Talocco C, Pizzoferrato M, Di Simone N, D'Ippolito S, Ricci C, Gervasoni J, Persichilli S, Del Chierico F, Marzano V, Mortera SL, Primiano A, Poscia A, Ponziani FR, Putignani L, Urbani A, Petito V, Di Vincenzo F, Masi L, Lopetuso LR, Cammarota G, Romualdi D, Lanzone A, Gasbarrini A, Scaldaferri F. Graziani C, et al. Among authors: pizzoferrato m. J Pers Med. 2022 Jun 20;12(6):1005. doi: 10.3390/jpm12061005. J Pers Med. 2022. PMID: 35743789 Free PMC article.
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.
Papa A, Scaldaferri F, Covino M, Tursi A, Furfaro F, Mocci G, Lopetuso LR, Maconi G, Bibbò S, Fiorani M, Laterza L, Mignini I, Napolitano D, Parisio L, Pizzoferrato M, Privitera G, Pugliese D, Schepis T, Schiavoni E, Settanni CR, Vetrone LM, Armuzzi A, Danese S, Gasbarrini A. Papa A, et al. Among authors: pizzoferrato m. Biomedicines. 2022 Apr 3;10(4):843. doi: 10.3390/biomedicines10040843. Biomedicines. 2022. PMID: 35453593 Free PMC article.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Tursi A, et al. Among authors: pizzoferrato m. Expert Opin Biol Ther. 2022 Feb;22(2):313-320. doi: 10.1080/14712598.2022.2007881. Epub 2021 Dec 27. Expert Opin Biol Ther. 2022. PMID: 34904510
30 results